Kodiak Sciences KOD 深 沪
等待开盘 12-17 09:30:00 美东时间
24.13
+1.110
+4.82%
华盛通- 最 高24.43
- 今 开21.69
- 成交量 113.03万股
- 最 低 21.50
- 昨 收 23.02
- 总市值 12.75亿
- 52周最高 26.21
- 市盈率 静 --
- 换手率 2.14%
- 52周最低 1.92
- 委 比 -58.36%
- 总股本 5282.17万
- 历史最高 171.21
- 量 比 2.02
- 振 幅 12.73%
- 历史最低 1.37
- 每 手 1
- 风险率 6.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kodiak Sciences shares are trading lower after the company announced a proposed public offering of 6 million shares.
Kodiak Sciences shares are trading lower after the company announced a proposed...
12-16 05:05
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $26
HC Wainwright & Co. analyst Matthew Caufield maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price target from $24 to $26.
11-17 19:53
Kodiak Sciences Q3 EPS $(1.16) Misses $(1.03) Estimate
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(1.03) by 12.51 percent. This is a 38.1 percent decrease over losses of $(0.84) per share from
11-14 05:29
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Kodiak Sciences Announces Data From APEX Trial Of KSI-101 In Patients With Macular Edema Secondary To Inflammation
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today follow-up data from the APEX
11-05 20:27
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
JP Morgan Upgrades Kodiak Sciences to Overweight, Raises Price Target to $24
JP Morgan analyst Anupam Rama upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Overweight and raises the price target from $15 to $24.
10-24 18:30
Kodiak to Report Third Quarter 2025 Results on November 12, 2025
Kodiak AI announced it will release its third quarter 2025 results on November 12, 2025, followed by a conference call at 5:00 PM ET (2:00 PM PT). The call can be accessed via a provided link or the company’s investor relations website, with an audio replay available. Founded in 2018, Kodiak AI specializes in AI-powered autonomous vehicle technology, focusing on commercial trucking and public sector applications. The company claims to be the firs...
10-22 13:00
【山证汽车】汽车智能驾驶专题（一）：智驾已是“必答题”，低阶配置平权与高阶功能落地共振
登录新浪财经APP 搜索【信披】查看更多考评等级 投资要点 近年来，智能已经是各家汽车企业的“必答题”，无论新能源、燃油车智能功能渗透率正在快...
10-22 08:45
